Thomas W T Leung

Summary

Affiliation: The Chinese University of Hong Kong
Country: China

Publications

  1. ncbi request reprint Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma
    T W Leung
    Department of Clinical Oncology, The Chinese University of Hong Kong, Shatin, New Territories
    Clin Cancer Res 5:1676-81. 1999
  2. ncbi request reprint Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy
    Thomas W T Leung
    Department of Clinical Oncology, The Chinese University of Hong Kong, SAR
    Cancer 94:421-7. 2002
  3. ncbi request reprint Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients
    Thomas W T Leung
    Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong SAR, China
    Cancer 94:1760-9. 2002
  4. ncbi request reprint Phase II study of the efficacy and safety of cisplatin-epinephrine injectable gel administered to patients with unresectable hepatocellular carcinoma
    T W T Leung
    Department of Clinical Oncology, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR, China
    J Clin Oncol 21:652-8. 2003
  5. ncbi request reprint A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma
    Winnie Yeo
    Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China
    J Natl Cancer Inst 97:1532-8. 2005
  6. ncbi request reprint Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy
    Winnie Yeo
    MRCP, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong winnieyeo cuhk edu hk
    J Clin Oncol 22:927-34. 2004
  7. pmc Salvage surgery following downstaging of unresectable hepatocellular carcinoma
    Wan Yee Lau
    Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China
    Ann Surg 240:299-305. 2004
  8. doi request reprint Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population
    Stephen L Chan
    State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, Hong Kong, China
    J Gastroenterol Hepatol 26:340-7. 2011
  9. ncbi request reprint A phase I safety and pharmacokinetic study of OGT 719 in patients with liver cancer
    Tony S K Mok
    Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, New Territories, Hong Kong, China
    Acta Oncol 43:245-51. 2004
  10. ncbi request reprint Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival
    Wan Yee Lau
    Department of Surgery, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR, China
    Ann Surg 247:43-8. 2008

Detail Information

Publications24

  1. ncbi request reprint Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma
    T W Leung
    Department of Clinical Oncology, The Chinese University of Hong Kong, Shatin, New Territories
    Clin Cancer Res 5:1676-81. 1999
    ..Complete pathological remission is possible with this systemic combination. Apparently, persistent radiological lesions may still represent complete pathological resolution of active disease...
  2. ncbi request reprint Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy
    Thomas W T Leung
    Department of Clinical Oncology, The Chinese University of Hong Kong, SAR
    Cancer 94:421-7. 2002
    ....
  3. ncbi request reprint Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients
    Thomas W T Leung
    Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong SAR, China
    Cancer 94:1760-9. 2002
    ....
  4. ncbi request reprint Phase II study of the efficacy and safety of cisplatin-epinephrine injectable gel administered to patients with unresectable hepatocellular carcinoma
    T W T Leung
    Department of Clinical Oncology, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR, China
    J Clin Oncol 21:652-8. 2003
    ..To study the efficacy and safety of percutaneous cisplatin-epinephrine (CDDP-EPI) injectable gel in patients with localized unresectable hepatocellular carcinoma (HCC)...
  5. ncbi request reprint A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma
    Winnie Yeo
    Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China
    J Natl Cancer Inst 97:1532-8. 2005
    ..Cisplatin, interferon, doxorubicin, and fluorouracil (PIAF) used in combination, by contrast, has shown promise in a phase II study. We compared doxorubicin to PIAF in patients with unresectable HCC in a phase III trial...
  6. ncbi request reprint Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy
    Winnie Yeo
    MRCP, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong winnieyeo cuhk edu hk
    J Clin Oncol 22:927-34. 2004
    ....
  7. pmc Salvage surgery following downstaging of unresectable hepatocellular carcinoma
    Wan Yee Lau
    Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China
    Ann Surg 240:299-305. 2004
    ..We reported here a series of 49 patients with unresectable hepatocellular carcinoma (HCC) who underwent nonsurgical treatment to downstage the disease followed by salvage surgery, their long-term outcome, and pattern of recurrence...
  8. doi request reprint Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population
    Stephen L Chan
    State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, Hong Kong, China
    J Gastroenterol Hepatol 26:340-7. 2011
    ..This study aims to validate CUPI and compare with other published staging systems...
  9. ncbi request reprint A phase I safety and pharmacokinetic study of OGT 719 in patients with liver cancer
    Tony S K Mok
    Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, New Territories, Hong Kong, China
    Acta Oncol 43:245-51. 2004
    ..None of the patients had a significant tumor response. Elimination half-life of OGT 719 by 3-h intravenous infusion is short and monophasic. Toxicity was minimal at the highest dose level...
  10. ncbi request reprint Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival
    Wan Yee Lau
    Department of Surgery, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR, China
    Ann Surg 247:43-8. 2008
    ..This study evaluated the long-term outcome...
  11. ncbi request reprint False-negative rate of abdominal sonography for detecting hepatocellular carcinoma in patients with hepatitis B and elevated serum alpha-fetoprotein levels
    Tony S K Mok
    Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China
    AJR Am J Roentgenol 183:453-8. 2004
    ....
  12. ncbi request reprint Transarterial chemoembolization for hepatocellular carcinoma
    W Y Lau
    Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, HKSAR, China
    J Am Coll Surg 202:155-68. 2006
  13. pmc Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future
    W Y Lau
    Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China
    Ann Surg 237:171-9. 2003
    ..To review and compare treatment result for percutaneous local ablative therapy (PLAT) with surgical resection in the treatment of small hepatocellular carcinoma (HCC)...
  14. ncbi request reprint Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes
    Terence C W Poon
    Department of Clinical Oncology, The Chinese University of Hong Kong, Shatin, Hong Kong, The People s Republic of China
    Clin Chem 49:752-60. 2003
    ..Detection of hepatocellular carcinoma (HCC) in patients with chronic liver disease (CLD) is difficult. We investigated the use of comprehensive proteomic profiling of sera to differentiate HCC from CLD...
  15. ncbi request reprint A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma
    Tony S K Mok
    Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China
    Cancer 95:1511-9. 2002
    ..The objectives of this study were to establish the maximum tolerated dose and to determine the efficacy of the sequential combination of intravenous topotecan and oral etoposide in the treatment of patients with SCLC...
  16. ncbi request reprint Transcriptional profiling identifies gene expression changes associated with IFN-alpha tolerance in hepatitis C-related hepatocellular carcinoma cells
    Nathalie Wong
    Department of Anatomical and Cellular Pathology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, N T, Hong Kong
    Clin Cancer Res 11:1319-26. 2005
    ..Hence, delineation of molecular targets implicated in the resistant pathway holds value in refining the therapeutic benefits of IFN-alpha...
  17. ncbi request reprint Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma
    Anthony T C Chan
    Department of Clinical Oncology, Sir Y K Pao Center for Cancer, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, N T Hong Kong
    J Natl Cancer Inst 97:536-9. 2005
    ..013, HR = 0.51 [95% CI = 0.3 to 0.88]), favoring the CRT arm. The regimen of weekly concurrent CRT is a promising standard treatment strategy for locoregionally advanced nasopharyngeal carcinoma patients...
  18. doi request reprint Current role of selective internal irradiation with yttrium-90 microspheres in the management of hepatocellular carcinoma: a systematic review
    Wan Yee Lau
    Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR, China
    Int J Radiat Oncol Biol Phys 81:460-7. 2011
    ..This article reviews the role of selective internal irradiation (SIR) with yttrium-90 ((90)Y) microspheres for hepatocellular carcinoma (HCC)...
  19. doi request reprint Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres
    Wan Yee Lau
    Faculty of Medicine, Chinese University of Hong Kong, Shatin, New Territories, Hong Kong
    Int J Radiat Oncol Biol Phys 82:401-7. 2012
    ..Its unique mode of action, including both (90)Y brachytherapy and embolization of neoplastic microvasculature, necessitates activity planning methods specific to SIRT...
  20. ncbi request reprint Quantification and utility of monosialylated alpha-fetoprotein in the diagnosis of hepatocellular carcinoma with nondiagnostic serum total alpha-fetoprotein
    Terence C W Poon
    Department of Clinical Oncology, the Sir Y K Pao Centre for Cancer, The Chinese University of Hong Kong, Shatin, Hong Kong
    Clin Chem 48:1021-7. 2002
    ..We describe two strategies for quantitative analysis of msAFP and explore their diagnostic accuracy in cases of HCC with nondiagnostic serum total AFP concentrations...
  21. ncbi request reprint Analysis of differentially expressed genes in hepatocellular carcinoma with hepatitis C virus by suppression subtractive hybridization
    Masayo Kotaka
    Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, N T Hong Kong
    Oncol Res 13:161-7. 2002
    ..Most of these genes have not been reported in HCC. Further characterization of these differentially expressed known and unknown genes will provide useful information in understanding the genes responsible for the development of HCC...
  22. ncbi request reprint Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer
    Winnie Yeo
    Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
    Anticancer Drugs 13:655-62. 2002
    ..We conclude that docetaxel-epirubicin chemotherapy is highly effective for recurrent metastatic/locoregional breast cancer, with myelosuppression being the main toxicity...
  23. doi request reprint Treatment of large and advanced hepatocellular carcinoma
    Eddie K Abdalla
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 15:979-85. 2008
  24. ncbi request reprint Panmucositis and chemosensitisation associated with betel quid chewing during dose-dense adjuvant breast cancer chemotherapy
    Richard J Epstein
    Division of Haematology Oncology, Department of Medicine, University of Hong Kong, Room 404, Professorial Block, Queen Mary Hospital, Pokfulam Rd, Pokfulam, Hong Kong
    Cancer Chemother Pharmacol 58:835-7. 2006
    ..Here, we report a case of fulminant panmucositis complicating dose-dense adjuvant breast cancer treatment in a betel-chewing patient without evidence of other risk factors...